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When overexpressed ar mutated, protein tyrosine kinases become potent oncoproteins that cause 
deregulated cell growth angiogenesis and metastasis. Because af these characteristics, they are 
targets for small molecule inhibilors in the Irealment of cancero Recently some thieno[3,2-c]pyridine 
1 ,3-diarylurea derivatives were prepared as VEGFR-2 (vascular endothelium grawth factor receptor-2) 
inhibitors.' Here we present the synthesis of methyl 3-[4-(3-arylureido)phenylamino]thieno[3,2-
b]pyridine-2-carboxylates 2 in excellent yields, by reaction of the methyl 3-(4-
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Scheme 
ln this study we used AutoDock Vi na to perform molecular docking in arder to evaluate the capacity of 
compounds 2 to inhibit VEGFR-2, a protein related to tumour angiogenesis. The pratein tyrasine 
kinase domain X-ray 3-D structure was obtained fram the Pratein Data Bank (PDB: 1YWN) and the 
estimated inhibition constants (Ki) of the compounds were obtained. ln arder to validate the molecular 
docking appraach, the respective co-crystallized ligand (LlF) and Sorafenib, a known drug that inhibits 
VEGFR-2, were docked to the kinase domain. The difference between the X-ray conformation and the 
predicted docked conformations of both ligands as well as the difference between estimated Ki 
(Sorafenib: 109 nM; LlF: 7 nM) and experimental Ki (Sorafenib: 93 nM',LlF: 2 nM') were negligible, 
validating "the protein structure for virtual screening with the synthesised compounds. An initial drug-
like analysis was performed by calculating several praperty parameters of the compounds and it was 
observed that ali compounds 2 obey the Lipinski's Rule of Five. ln this series compound 2c is the most 
promising one presenting an estimated Ki value of 214 nM against 5276 nM for 2a and 497nM for 2b. 
The presence of the nitrile group lowers significantly the Ki vai ue in this series. 
Furthermore, the docking pose of the compound with the best docking score was analyzed in arder to 
understand the key interactions between the compounds and the VEGFR-2 kinase domain structure. 
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